Evidence map›Paper›PMID 31729834›Full record

ArticleThe Kaohsiung journal of medical sciences2020

MiR-291a-3p regulates the BMSCs differentiation via targeting DKK1 in dexamethasone-induced osteoporosis.

Zhe-Hai Li, He Hu, Xiao-Yan Zhang, Guo-Dong Liu, Bo Ran, Pei-Guang Zhang, Ming-Mei Liao, Yu-Chi Wu

Open access · goldAbstract read
In one paragraph

Article in The Kaohsiung journal of medical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. International journal of molecular sciences · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Drug Discovery of DKK1 Inhibitors.Frontiers in pharmacology · 2022
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Zhe-Hai LiDepartment of Orthopedics, Peking University Third Hospital, Beijing, P.R. China.
He HuDepartment of Orthopedics, The Inner Mongolia People's Hospital, Hohhot, China.
Xiao-Yan ZhangDepartment of Orthopedics, The Third Affiliated Hospital of Inner Mongolia Medical University, Baotou, China.
Guo-Dong LiuDepartment of Orthopedics, The Third Affiliated Hospital of Inner Mongolia Medical University, Baotou, China.
Bo RanDepartment of Orthopedics, The Third Affiliated Hospital of Inner Mongolia Medical University, Baotou, China.
Pei-Guang ZhangDepartment of Orthopedics, The Third Affiliated Hospital of Inner Mongolia Medical University, Baotou, China.
Ming-Mei LiaoKey Laboratory of Nanobiological Technology of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha, China.
Yu-Chi WuDepartment of Orthopedics, The Third Affiliated Hospital of Inner Mongolia Medical University, Baotou, China.ORCID https://orcid.org/0000-0001-5301-2935
Third Affiliated Hospital of Inner Mongolia Medical College · CNCentral South University · CNInner Mongolia People's Hospital · CNPeking University · CN

Funding

National Natural Science Foundation of China 30860288National Natural Science Foundation of China 81260285
6 · The paper itself

Abstract

Osteoporosis is a skeleton disease affecting 55% of people over age 60, and the number is still increasing due to an ageing population. One method to prevent osteoporosis is to increase the formation of new bone while preventing the resorption of older bone. Thus, osteogenic differentiation of bone marrow-derived mesenchymal stem cells (BMSCs) is of great importance in improving the treatment of osteoporosis. On the other hand, glucocorticoids (GCs) are widely used to treat the chronic inflammatory disorders, but long-term exposure to GCs can induce osteoporosis. In present study, we treated BMSCs with dexamethasone (DEX) to simulate GC-induced osteoporosis. MTT assay, ALP activity, and Alizarin Red were used to evaluate the role miRNA-291a-3p in the DEX-induced osteogenic differentiation suppression. Further, we used qPCR and western blot to investigate the mechanisms of miRNA-291a-3p affecting BMSCs differentiation. The results showed that miRNA-291a-3p could improve the cell viability, osteogenic differentiation, and ALP activity, which are suppressed by DEX in BMSCs. Furthermore, we found that the osteogenesis genes Runx2, DMP1, and ALP were upregulated whereas the lipogenic genes C/EBPα and PPARγ were downregulated when miRNA-291a-3p mimics were transfected. Additionally, we demonstrated that miRNA-291a-3p promoted BMSCs' osteogenic differentiation by directly suppressing DKK1 mRNA and protein expression and subsequently activating Wnt/β-catenin signaling pathway. Our study suggests that miR-291a-3p plays an important role in preventing osteoporosis and may serve as a potential miRNA osteoporosis biomarker.

Indexed as

AnimalsBlotting, WesternCell DifferentiationCell SurvivalDexamethasoneHumansIntercellular Signaling Peptides and ProteinsMaleMesenchymal Stem CellsMicroRNAsOsteogenesisOsteoporosisRatsRats, Sprague-DawleyDexamethasoneDkk1 protein, ratIntercellular Signaling Peptides and ProteinsMicroRNAsBMSCsDEXDKK1miR-291a-3posteogenic differentiation

Identifiers

PMID31729834
PMCPMC11896440
OpenAlexW2982954614

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.